CHARM Therapeutics

About CHARM Therapeutics

CHARM Therapeutics is focused on delivering transformational medicines by understanding protein-ligand interactions, with a pioneering approach to developing next-generation small molecule therapeutics, particularly menin inhibitors for Acute Myeloid Leukemia (AML).

Products & Services

Next Generation Menin Inhibitors:Designed to reprogram leukemic cells in AML by preventing cancerous interactions, overcoming treatment resistance with highly potent and precisely binding inhibitors.

Specialties

Protein-ligand interactions Small molecule therapeutics Menin inhibitors for AML AI in drug discovery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 80000000 MR: - FA: $80 million FAN: 80000000	D: 2025-09-02 FD: 2025-09-02	6 investors
2	RT: Venture Investment T: - FT: Venture Investment	A: 70000000 MR: - FA: $70 million FAN: 70000000	D: 2023-05-15 FD: 2023-05-15	1 investors

Series B Latest

2025-09-02

$80.0M

6 investors (Pro only)

Venture Investment 2023-05-15

$70.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Gary D. Glick

Executive Chair

B

Beverley Carr

Chief Business Officer

L

Laura Hare

Chief Operating Officer

N

Nick Edmunds

Chief Development Officer

N

Nihal Sinha

Investor Director

R

Rishi Gupta

Investor Director

View 9 more team members with Pro

Unlock Full Team Directory

Recent News